The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
TipRanks on MSN
BioCryst gains FDA approval for pediatric HAE drug
BioCryst ( ($BCRX) ) has provided an announcement. On December 12, 2025, BioCryst Pharmaceuticals announced the FDA approval of its new drug ...
Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four ...
The US Food and Drug Administration (FDA) agency is proposing to add bemotrizinol as a permitted active ingredient for use in ...
The U.S. has been missing out on some of the world's best sunscreens, but we're finally getting bemotrizinol, and I'm excited ...
The FDA approval of berotralstat oral pellets offers a new prophylaxis option for children aged 2 years and older with hereditary angioedema.
ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...
The 2024–2025 formulations of COVID-19 vaccines had an effectiveness rate of 76% at preventing emergency or urgent care ...
In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...
Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback